Literature DB >> 26817958

Strategies that delay or prevent the timely availability of affordable generic drugs in the United States.

Gregory H Jones1, Michael A Carrier2, Richard T Silver3, Hagop Kantarjian4.   

Abstract

High cancer drug prices are influenced by the availability of generic cancer drugs in a timely manner. Several strategies have been used to delay the availability of affordable generic drugs into the United States and world markets. These include reverse payment or pay-for-delay patent settlements, authorized generics, product hopping, lobbying against cross-border drug importation, buying out the competition, and others. In this forum, we detail these strategies and how they can be prevented.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26817958      PMCID: PMC4915805          DOI: 10.1182/blood-2015-11-680058

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Unsettling drug patent settlements: a framework for presumptive illegality.

Authors:  Michael A Carrier
Journal:  Mich Law Rev       Date:  2009-10

2.  Access, affordability, and insurance complexity are often worse in the United States compared to ten other countries.

Authors:  Cathy Schoen; Robin Osborn; David Squires; Michelle M Doty
Journal:  Health Aff (Millwood)       Date:  2013-11-13       Impact factor: 6.301

3.  Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs.

Authors:  Hagop Kantarjian; Michael S Mathisen; Jeffrey H Lipton
Journal:  JAMA Oncol       Date:  2015-09       Impact factor: 31.777

4.  The rise in health care coverage and affordability since health reform took effect: findings from the Commonwealth Fund Biennial Health Insurance Survey, 2014.

Authors:  Sara R Collins; Petra W Rasmussen; Michelle M Doty; Sophie Beutel
Journal:  Issue Brief (Commonw Fund)       Date:  2015-01

5.  Intellectual property. Drug patents at the Supreme Court.

Authors:  C Scott Hemphill; Bhaven Sampat
Journal:  Science       Date:  2013-03-22       Impact factor: 47.728

Review 6.  Why are cancer drugs so expensive in the United States, and what are the solutions?

Authors:  Hagop Kantarjian; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2015-03-16       Impact factor: 7.616

7.  Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise.

Authors:  Nicholas S Downing; Joseph S Ross; Cynthia A Jackevicius; Harlan M Krumholz
Journal:  Arch Intern Med       Date:  2012-05-14

8.  In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:  Ayalew Tefferi; Hagop Kantarjian; S Vincent Rajkumar; Lawrence H Baker; Jan L Abkowitz; John W Adamson; Ranjana Hira Advani; James Allison; Karen H Antman; Robert C Bast; John M Bennett; Edward J Benz; Nancy Berliner; Joseph Bertino; Ravi Bhatia; Smita Bhatia; Deepa Bhojwani; Charles D Blanke; Clara D Bloomfield; Linda Bosserman; Hal E Broxmeyer; John C Byrd; Fernando Cabanillas; George Peter Canellos; Bruce A Chabner; Asher Chanan-Khan; Bruce Cheson; Bayard Clarkson; Susan L Cohn; Gerardo Colon-Otero; Jorge Cortes; Steven Coutre; Massimo Cristofanilli; Walter J Curran; George Q Daley; Daniel J DeAngelo; H Joachim Deeg; Lawrence H Einhorn; Harry P Erba; Francisco J Esteva; Elihu Estey; Isaiah J Fidler; James Foran; Stephen Forman; Emil Freireich; Charles Fuchs; James N George; Morie A Gertz; Sergio Giralt; Harvey Golomb; Peter Greenberg; Jordan Gutterman; Robert I Handin; Samuel Hellman; Paulo Marcelo Hoff; Ronald Hoffman; Waun Ki Hong; Mary Horowitz; Gabriel N Hortobagyi; Clifford Hudis; Jean Pierre Issa; Bruce Evan Johnson; Philip W Kantoff; Kenneth Kaushansky; David Khayat; Fadlo R Khuri; Thomas J Kipps; Margaret Kripke; Robert A Kyle; Richard A Larson; Theodore S Lawrence; Ross Levine; Michael P Link; Scott M Lippman; Sagar Lonial; Gary H Lyman; Maurie Markman; John Mendelsohn; Neal J Meropol; Yoav Messinger; Therese M Mulvey; Susan O'Brien; Roman Perez-Soler; Raphael Pollock; Josef Prchal; Oliver Press; Jerald Radich; Kanti Rai; Saul A Rosenberg; Jacob M Rowe; Hope Rugo; Carolyn D Runowicz; Brenda M Sandmaier; Alan Saven; Andrew I Schafer; Charles Schiffer; Mikkael A Sekeres; Richard T Silver; Lillian L Siu; David P Steensma; F Marc Stewart; Wendy Stock; Richard Stone; Rainer Storb; Louise C Strong; Martin S Tallman; Michael Thompson; Naoto T Ueno; Richard A Van Etten; Julie M Vose; Peter H Wiernik; Eric P Winer; Anas Younes; Andrew D Zelenetz; Charles A LeMaistre
Journal:  Mayo Clin Proc       Date:  2015-07-23       Impact factor: 7.616

9.  Patented drug extension strategies on healthcare spending: a cost-evaluation analysis.

Authors:  Nathalie Vernaz; Guy Haller; François Girardin; Benedikt Huttner; Christophe Combescure; Pierre Dayer; Daniel Muscionico; Jean-Luc Salomon; Pascal Bonnabry
Journal:  PLoS Med       Date:  2013-06-04       Impact factor: 11.069

  9 in total
  9 in total

Review 1.  Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.

Authors:  S Vincent Rajkumar; Jean Luc Harousseau
Journal:  Blood       Date:  2016-10-14       Impact factor: 22.113

2.  The Challenge of High Drug Prices in America: Cost Disclosure in Direct-to-Consumer Advertising May Offer a Solution.

Authors:  Kamille Garness
Journal:  Am Health Drug Benefits       Date:  2019-09

Review 3.  The high price of anticancer drugs: origins, implications, barriers, solutions.

Authors:  Vinay Prasad; Kevin De Jesús; Sham Mailankody
Journal:  Nat Rev Clin Oncol       Date:  2017-03-14       Impact factor: 66.675

4.  Targeted therapy: Generic imatinib - impact on frontline and salvage therapy for CML.

Authors:  Larry Gorkin; Hagop Kantarjian
Journal:  Nat Rev Clin Oncol       Date:  2016-05       Impact factor: 66.675

5.  US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer Acetate.

Authors:  Benjamin N Rome; Frazer A Tessema; Aaron S Kesselheim
Journal:  JAMA Intern Med       Date:  2020-09-01       Impact factor: 21.873

6.  Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs.

Authors:  Irene B Murimi-Worstell; Jeromie M Ballreich; Marissa J Seamans; G Caleb Alexander
Journal:  PLoS One       Date:  2019-11-12       Impact factor: 3.240

7.  An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004-2018).

Authors:  Mahanjit Konwar; Mitesh R Maurya; Tushar B Nishandar; Urmila M Thatte; Nithya J Gogtay
Journal:  Perspect Clin Res       Date:  2021-01-08

8.  A dashboard for exploring clinical trials sponsorship and potential virtual monopolies.

Authors:  S Scott Graham; Zoltan P Majdik; Joshua B Barbour; Justin F Rousseau
Journal:  JAMIA Open       Date:  2021-10-29

Review 9.  Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States.

Authors:  Vishwanath Sathyanarayanan; Christopher R Flowers; Swaminathan P Iyer
Journal:  JCO Glob Oncol       Date:  2020-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.